Generation Bio Co. rose 1.65% in intraday trading, with the company's stock price movement aligning with the positive financial performance of Junshi Biosciences, a leading biopharmaceutical company. Junshi Biosciences reported a 49% increase in total revenue for the first half of 2025, driven mainly by pharmaceutical sales, with its core product, TUOYI® (toripalimab), contributing significantly to this growth.
Comments
No comments yet